Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 301 AL 315

Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease

Labrador-Espinosa MA, Franzmeier N, Karagianni S, Moscoso A, Schöll M.

Alzheimers Res Ther. 2026 Jun 24;18(1):154. doi: 10.1186/s13195-026-02123-3.

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration

Birditt KR, Mavromati K, Swann P, Quinn T, Hainsworth AH, Hughes L, O'Brien JT, McEwan W, Malpetti M.

Alzheimers Dement. 2026 Jul;22(7):e71642. doi: 10.1002/alz.71642.

Volumetric postmortem MRI of the medial temporal lobe in Alzheimer's disease and related disorders: methodological advances and implications for in vivo biomarker development

Salman Y, Denning AE, Schaeverbeke JM, Tomé SO, Joudiou N, Khandelwal P, Yushkevich PA, Vandenberghe R, Gallez B, Wisse LE, Hanseeuw BJ.

Neuroimage. 2026 Sep;338:122098. doi: 10.1016/j.neuroimage.2026.122098. Epub 2026 Jul 2.

Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease

Moghekar AR, Rock JA, Mohs RC, Hansson O, Stomrud E, Palmqvist S, Mattsson-Carlgren N, Johnson SC, Zetterberg H, Radwan RR, Junfola J, Miller MC, Buitrago L, De Simone FI, Martin K, Dickson D, Benina N, Hawkins DM.

Alzheimers Dement. 2026 Jul;22(7):e71644. doi: 10.1002/alz.71644.

Targeting the pathological tau N368 fragment: A pharmacological perspective on a novel immunotherapy for Alzheimer's disease

Qian Z, Hu Z, Li Y, Zuo D, He R, Ye K.

Pharmacol Res. 2026 Sep;231:108337. doi: 10.1016/j.phrs.2026.108337. Epub 2026 Jul 9.

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Bittner T, Lopera F, Rios-Romenets S, Schiffman C, Clayton D, Hibar D, Kollmorgen G, Dolton M, Poon V, Nguyen J, Giraldo-Chica M, Acosta-Baena N, Espinosa A, Villegas G, Muñoz C, Serna L, Alvarez S, Protas H, Luo J, Sohankar J, Chen Y, Ghisays V, Malek-Ahmadi M, Ashton NJ, Denkinger MN, Cai Y, Xu YR, Ostaszewski B, Selkoe DJ, Alexander RC, Quiroz YT, Su Y, Chen K, Doody RS, Langbaum JB, Tariot PN, Sink KM, Reiman EM.

EBioMedicine. 2026 Aug;130:106390. doi: 10.1016/j.ebiom.2026.106390. Epub 2026 Jul 17.

Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies

Yanagisawa D, Ohgita T, Kawashima H, Yoshikawa H, Saito H, Tooyama I, Takata K.

Pharmacol Ther. 2026 Oct;286:109084. doi: 10.1016/j.pharmthera.2026.109084. Epub 2026 Jul 19.

Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review

Li C, Fu M, Berg K, Wallach J, Ling K, Wei R, Shi L, Ross J, Guan X.

Neurology. 2026 Aug 25;107(4):e218373. doi: 10.1212/WNL.0000000000218373. Epub 2026 Jul 23.

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials

Vamanu A, Mastaleru A, Schreiner TG, Popescu G, Roceanu AM, Cucu AI, Patrascu A, Vulpoi GA, Bilcu RV, Cozma RS, Olariu R, Bistriceanu CE, Covali R, Cuciureanu DI, Ciubotaru A.

Med Sci (Basel). 2026 Jun 23;14(3):337. doi: 10.3390/medsci14030337.

Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study

Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y.

Alzheimers Dement. 2026 Aug;22(8):e71702. doi: 10.1002/alz.71702.

A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease

Lynch SY, Wang Y, Wang D, Bachhav SS, Xiong H, Boiser J, Stage E, Bannon AW, Graff O, Florian H.

Alzheimers Dement. 2026 Aug;22(8):e71715. doi: 10.1002/alz.71715.

Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

Collins EC, Lu M, Beck R, Hendrix J, Hodsdon ME, Hansson O.

Alzheimers Dement. 2026 Aug;22(8):e71740. doi: 10.1002/alz.71740.

Multi-Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Thakur A, Rana M, Vanjani S, Liou KC, Taliyan R, Nepali K, Yang CH.

Med Res Rev. 2026 Jul;46(4):1173-1229. doi: 10.1002/med.70047. Epub 2026 Apr 19.

Exploring the Potential of Herbal Compounds as Autophagy Modulators in Alzheimer's Disease: A Comprehensive Review

Yadav E, Mandal AK, Sah AK, Poudel S, Pathak P, Khalilullah H, Jaremko M, Emwas AH, Yadav P, Verma A.

CNS Neurol Disord Drug Targets. 2026;25(2):78-103. doi: 10.2174/0118715273298025240905130205.

Rethinking on bile acid-brain axis: decoding neurotoxic and neuroprotective landscape in aging and Alzheimer's disease

Singh G, Aran KR.

Biogerontology. 2026 Jan 12;27(1):37. doi: 10.1007/s10522-025-10384-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias